Mylan gets partial win over Sanofi move to dismiss US antitrust claims
Mylan has been granted a partial win over Sanofi-Aventis's motion to dismiss Mylan's US antitrust claims over alleged monopolization and biosimilar delay in the market for injectable insulin glargine, losing on its...To view the full article, register now.
Already a subscriber? Click here to view full article